How Stryker Makes its Money: Revenue Breakdown
A breakdown of Stryker (SYK) financials. See how Stryker makes money from MedSurg & Neurotechnology, Orthopaedics & Spine using their 2024 annual report.
How Does Stryker Make its Money?
Stryker is one of the world’s leading medical technology companies, specializing in orthopaedic implants, surgical instruments, and neurotechnology. The company’s products range from hip and knee replacements to surgical navigation systems, endoscopy equipment, and hospital beds. Stryker is known for its Mako robotic-arm assisted surgery platform, which has become a key growth driver in orthopaedics. The company has a strong track record of acquisitive growth, completing numerous bolt-on acquisitions annually.
Stryker’s competitive advantage comes from the combination of a massive installed base of surgical instruments (hospitals invest significant capital in Stryker equipment and then buy procedure-specific disposables), the Mako robotic platform (which creates surgeon loyalty and switching costs), and the most prolific acquisition engine in medtech. The company has completed over 50 acquisitions in the past decade, using its scale and distribution network to commercialize acquired technologies far more effectively than the smaller companies could on their own.
Stryker (SYK) Business Model
Stryker Competitors
Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| MedSurg & Neurotechnology | $14,100 | $12,900 | +9.3% |
| Orthopaedics & Spine | $8,500 | $7,800 | +9.0% |
| Total Revenue | $22,600 | $20,500 | +10.2% |
MedSurg & Neurotechnology — 62% of Revenue
The larger of Stryker’s two segments, MedSurg & Neurotechnology, encompasses surgical equipment, endoscopy devices, patient handling equipment (hospital beds, stretchers), neurovascular devices, and neurosurgical instruments. Key product lines include the Stryker 1688 4K camera system for minimally invasive surgery, Neptune waste management system (used in virtually every leading hospital operating room), and ProCuity hospital bed platform with integrated patient monitoring.
The neurotechnology franchise includes devices for hemorrhagic and ischemic stroke treatment (clot retrieval catheters, flow diverters, coils), spinal neuromodulation for chronic pain, and neurosurgical instruments. Stryker has built a strong position in the neurointerventional market through acquisitions, most notably the 2020 purchase of Wright Medical (focused on extremities and biologics). Growth of 9.3% in 2024 was driven by procedure volume recovery, new product launches, and continued penetration of the Mako robot-assisted platform into surgical specialties beyond hip and knee replacements.
Orthopaedics & Spine — 38% of Revenue
Orthopaedics & Spine covers joint replacement implants (hips, knees, shoulders), trauma fixation devices (plates, screws, nails for fractures), spine implants (fusion cages, pedicle screws), and the Mako robotic-arm assisted surgery platform. Stryker is the #2 global player in orthopaedic implants behind Johnson & Johnson’s DePuy Synthes division.
The Mako robot has been transformative for this segment. Hospitals that invest in Mako systems (priced at roughly $1-1.5 million per unit) tend to use Stryker implants for the procedures performed on the robot, creating a powerful pull-through effect for hip and knee implant sales. Over 2,000 Mako robots have been installed globally, and the platform is expanding into new indications including shoulder replacements and spine procedures. Revenue grew 9.0% in 2024, with Mako-enabled procedures growing faster than the overall joint replacement market as the installed base expanded and utilization rates increased at existing sites.
Stryker (SYK) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $22,600 | $20,500 |
| Cost of Revenue | $8,700 | $8,100 |
| Gross Profit | $13,900 | $12,400 |
| Operating Expenses | $9,400 | $8,600 |
| Operating Income | $4,500 | $3,800 |
| Net Income | $3,500 | $3,000 |
All values in millions USD unless otherwise stated.
Financial data sourced from Stryker SEC Filings.
Stryker (SYK) Key Financial Metrics
- Gross Margin: 61.5%
- Operating Margin: 19.9%
- Revenue Growth: 10.2%
Is Stryker Profitable?
Yes, Stryker is solidly profitable with margins expanding as the Mako platform scales. The 61.5% gross margin is strong for a medical device company that manufactures physical products (implants, surgical instruments, hospital beds), reflecting the premium pricing power of differentiated medical technology. Operating margin of 19.9% has room for expansion — management has outlined a path toward 22-23% operating margins through volume leverage, manufacturing efficiencies, and the ongoing shift toward higher-margin robotic surgery and disposable components. Net income grew 17% to $3.5 billion in 2024, outpacing revenue growth as operating leverage kicked in. Stryker also generates strong free cash flow, which funds the company’s acquisitive growth strategy while maintaining a manageable balance sheet.
Stryker (SYK): What to Watch
- Mako installed base expansion — The robotic platform is central to Stryker’s orthopaedic growth strategy. Each new Mako installation drives years of pull-through implant and disposable sales. Expansion into shoulder and spine procedures would significantly increase the total addressable market for the robot.
- Operating margin trajectory — Stryker has historically operated at slightly lower margins than some medtech peers (Boston Scientific, Intuitive Surgical). Achieving the 22-23% operating margin target would meaningfully boost earnings and demonstrate the company’s ability to grow profits faster than revenue.
- Acquisition integration — Stryker is one of the most active acquirers in medtech. The pipeline of bolt-on deals needs to deliver revenue synergies and margin accretion to justify the continued M&A cadence. Larger deals carry integration risk.
- Hospital capital spending — Stryker’s surgical equipment and Mako robot sales are capital expenditures for hospitals. A prolonged period of hospital financial stress or reduced capital budgets could slow equipment adoption.
- Competitive robotics landscape — Intuitive Surgical dominates in soft-tissue surgery with da Vinci, and several competitors (Zimmer Biomet’s ROSA, J&J’s VELYS) are launching competing orthopaedic robotics platforms. Stryker must continue innovating to maintain its Mako advantage.
Stryker (SYK) Financial Summary
Stryker delivered 10.2% revenue growth to $22.6 billion in 2024, demonstrating consistent execution across both the MedSurg & Neurotechnology segment (62% of revenue, growing 9.3%) and Orthopaedics & Spine (38%, growing 9.0%). The Mako robotic platform continues to be a differentiated growth engine, with the installed base exceeding 2,000 systems and expanding beyond hip and knee surgery into shoulder and spine applications. The 61.5% gross margin and 19.9% operating margin are healthy and trending higher as robotic surgery scales, and net income grew 17% to $3.5 billion. Stryker’s combination of high-single-digit organic growth, disciplined M&A, and margin expansion gives it one of the most reliable earnings compounding profiles in the medical device sector.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.